Calluna Pharma launches and announces €75m Series A financing to develop novel therapies for inflammatory and fibrotic diseases

January 23, 2024 – Drug Discovery, Pharmaceutical – Arxx Therapeutics, Calluna Pharma, Oxitope Pharma, funding

• Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics
• Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases
• New company to complete multiple clinical proofs-of-concept, across programmes
• Series A led by Forbion, with participation from Norwegian investors Sarsia, p53 and Investinor.

23 January 2024 — Naarden, The Netherlands, and Oslo, Norway — Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to form Calluna Pharma. Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53 and Investinor. The new company will combine expertise in the field of innate immunity, based on damage-associated molecular patterns (DAMPs), with a pipeline of selective antibodies that target inflammatory and fibrotic indications, including several first-in-class clinical candidates.

Calluna is developing novel therapies that harness the transformative potential of the body’s immune system. The company’s unique approach involves precision targeting of upstream innate immune amplifiers, enabling disruption of a comprehensive range of disease-associated downstream signalling pathways while maintaining a favourable safety profile. As a result, Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These include novel therapeutic candidates that fulfil unmet clinical needs across a spectrum of diseases, driven by acute or chronic inflammation and non-resolving tissue fibrosis.

Calluna has four promising therapies in its pipeline. Its clinical stage lead programme, CAL101, is a monoclonal antibody that neutralises the bioactivity of S100A4, a DAMP protein implicated in serious and life-threatening diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, rheumatoid arthritis and severe (steroid insensitive) asthma. Of particular interest is another of its programmes, CAL102, a monoclonal antibody neutralising oxidised phospholipids – these play a significant role in onset and progression of a wide range of acute and chronic inflammatory and fibrotic diseases. CAL102 demonstrated efficacy in several preclinical disease models.

John Montana PhD, chief executive officer of Calluna Pharma, commented: “In joining forces, these two key players in the innate immunology space have created an exciting new clinical company that has four promising therapies in its pipeline with excellent preclinical proof-of-concept data. By innovating beyond traditional treatment strategies, Calluna offers clinical candidates with superior efficacy, improved patient tolerance and minimal adverse side effects which have real potential to redefine patient outcomes.”

Antoine Boulanger PhD, principal at Forbion, added: “The merger of Oxitope Pharma and Arxx Therapeutics to create Calluna Pharma is a prime example of our Forbion Ventures Fund’s strategy where we both build new and enable existing companies. As a result, we recognised the strength of combining these two companies’ pioneering approaches to disrupt the treatment of inflammatory and fibrotic diseases, the complementarity of management skills and the resulting robust clinical pipeline. We look forward to continuing our support of potentially life changing clinical assets moving into the next phases of clinical development.”

Sveinung Hole MBA, managing partner at Sarsia (ex-chair at Arxx Therapeutics) and Susanne Stuffers MD PhD, managing partner at p53, commented: “Sarsia and p53 strive to bring cutting edge ideas and therapies from early-phase to clinical development and beyond to benefit patients and transform people’s lives. Calluna Pharma epitomises this, and we are enthusiastic to join forces with Forbion and to contribute to the success of this new entity.”

The company’s board of directors will include John Montana, operating partner (Forbion), as chief executive officer; Antoine Boulanger, principal (Forbion); Susanne Stuffers (p53); Farzad Abdi-Dezfuli general partner (Sarsia); and Marco Boorsma, general partner (Forbion) as chairman. The company is raising further financing to develop its pipeline to multiple key clinical milestones over the next 2.5 years.

About Calluna Pharma

Calluna Pharma is a clinical stage company pioneering a breakthrough approach to treating inflammatory and fibrotic diseases by leveraging the body’s innate immune system. The company’s therapeutic approach targets upstream amplifiers of disease, offering potential applicability across a diverse array of medical conditions. Calluna has a robust pipeline of selective antibodies targeting immunological diseases with enhanced efficacy, including several first-in-class clinical candidates. Calluna Pharma was formed in 2023 following the merger of Oxitope Pharma and Arxx Therapeutics. The Ccmpany is based in Oslo, Norway, with Forbion, Sarsia, p53 and Investinor as lead investors. Visit: www.callunapharma.com